Summarized by Masters of Longevity from Cambrian Bio.
RA Capital Management and Future Ventures joined the financing as ATX-304 entered Phase 1b testing for cardiometabolic disease.
Key Takeaways
- The $33.25 million figure is the total Series A, not the new investment alone.
- Proceeds support ATX-304 development for cardiometabolic and aging-related diseases.
- The Phase 1b study assessed safety and drug exposure; clinical benefit remained unproven.
